Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Vespa Laboratories is a specialized biotechnology company focused on the production of allergenic extracts for the diagnosis and treatment of Hymenoptera (stinging insect) venom allergies. Based in Spring Mills, Pennsylvania, the company is a primary global supplier of venom products used in venom immunotherapy (VIT). Its portfolio includes extracts from honey bees, yellow jackets, hornets, and wasps, which are critical for patients at risk of life-threatening anaphylactic reactions. Since its acquisition by ALK-Abelló in 1992, Vespa Laboratories has operated as a key manufacturing and research site within ALK's global allergy immunotherapy network. The facility is one of the few in the world capable of producing standardized venom at scale for clinical use. It maintains extensive insect collection operations to ensure the quality and consistency of its biological raw materials.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Vespa Laboratories.